Amoxicillin/Vonoprazan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Amoxicillin/Vonoprazan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Amoxicillin/Vonoprazan can convert its Small molecule drug profile and H+/K+ ATPase biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Amoxicillin/Vonoprazan (query alias: Amoxicillin/Vonoprazan) |
|---|---|
| Modality / target | Small molecule drug; H+/K+ ATPase; P-CAB |
| Highest global status | Approved |
| Originator | Phathom Pharmaceuticals, Inc. |
| Active developers | Phathom Pharmaceuticals, Inc., Triastek, Inc. |
The MCP disease footprint includes Helicobacter pylori infection. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600127614 | Phase 4 | Not yet recruiting | 125 | Helicobacter pylori (Hp) eradication rate |
| NCT07694531 | Not Applicable | Completed | 176 | Assessment of the extraction socket healing of both the groups using a modified Landry's Wound Healing Index |
| ChiCTR2600128447 | Not Applicable | Recruiting | 100 | Hp eradication rate |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age
Phase 4; n=1; evaluation: not stated. Reported fields: -; -; -
Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)
Phase 4; n=5; evaluation: not stated. Reported fields: Other (Not Including Serious) Adverse Events = 0 Participants ; -; -
Efficacy and Safety of Vonoprazan‐Based Dual Therapies With Different Antibiotics Versus Bismuth‐Containing Quadruple Therapy for <scp> <i>Helicobacter pylori</i> </scp> Eradication: A Prospective, Four‐Arm, Randomized Controlled Trial
Phase 4; n=400; evaluation: Positive. Reported fields: H Pylori eradication rates(ITT) = 83.0 % ; H Pylori eradication rates(ITT) = 74.0 % ; H Pylori eradication rates(ITT) = 83.0 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Amoxicillin/Vonoprazan addresses Helicobacter pylori infection. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 27 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: H+/K+ ATPase records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-06-11 | Onconic Therapeutics Enters Indonesia With Zacuvo Supply Deal | Approved | Financial terms not disclosed |
| 2025-12-07 | 华东医药与生诺医药就消化系统1.1类新药利那拉生酯达成独家商业化合作 | Approved | Financial terms not disclosed |
| 2025-11-18 | 上药信谊与生诺生物终止对 X842项目的合作 | Approved | US$11.1M upfront; US$98.2M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
